<DOC>
	<DOC>NCT02554773</DOC>
	<brief_summary>The purpose of this study is to evaluate the long-term safety and tolerability of ALN-AT3SC in male patients with moderate or severe hemophilia A or B.</brief_summary>
	<brief_title>An Open-label Extension Study of an Investigational Drug, ALN-AT3SC, in Patients With Moderate or Severe Hemophilia A or B</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Hemophilia B</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Completed and tolerated study drug dosing in study ALNAT3SC001 Male aged ≥18 years Moderate or severe, clinically stable hemophilia A or B Agree to use 1 effective method of contraception throughout study participation and until 1 month after administration of the last dose of study drug Willing and able to comply with the study requirements and provide written informed consent Clinically significant liver disease Patients known to be human immunodeficiency virus seropositive and have a CD4 count &lt;200 cells/μL History of venous thromboembolism Current serious mental illness that, in the judgment of the Investigator, may compromise patient safety, ability to participate in all study assessments, or study integrity Clinically relevant history or presence of cardiovascular, respiratory, gastrointestinal, renal, neurological, inflammatory, or other diseases that, in the judgment of the Investigator, precludes study participation</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Hemophilia</keyword>
	<keyword>RNAi therapeutic</keyword>
</DOC>